Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic
Authors:
Top Cited Papers
Open Access
- 6 May 2020
- journal article
- research article
- Published by Springer Nature in Harm Reduction Journal
- Vol. 17 (1) , 1-7
Abstract
The impact of COVID-19 across health services, including treatment services for people who use drugs, is emerging but likely to have a high impact. Treatment services for people who use drugs provide essential treatment services including opiate agonist treatment and needle syringe programmes alongside other important treatment programmes across all substance types including withdrawal and counselling services. Drug and alcohol hospital consultation-liaison clinicians support emergency departments and other services provided in hospital settings in efficiently managing patients who use drugs and present with other health problems.COVID-19 will impact on staff availability for work due to illness. Patients may require home isolation and quarantine periods. Ensuring ongoing supply of opiate treatment during these periods will require significant changes to how treatment is provided. The use of monthly depot buprenorphine as well as moving from a framework of supervised dosing will be required for patients on sublingual buprenorphine and methadone. Ensuring ready access to take-home naloxone for patients is crucial to reduce overdose risks. Delivery of methadone and buprenorphine to the homes of people with confirmed COVID-19 infections is likely to need to occur to support home isolation.People who use drugs are likely to be more vulnerable during the COVID-19 epidemic, due to poorer health literacy and stigma and discrimination towards this group. People who use drugs may prioritise drug use above other health concerns. Adequate supply of clean injecting equipment is important to prevent outbreaks of blood-borne viruses. Opiate users may misinterpret SARS-CoV2 symptoms as opiate withdrawal and manage this by using opioids. Ensuring people who use drugs have access to drug treatment as well as access to screening and testing for SARS-CoV2 where this is indicated is important.Keywords
This publication has 22 references indexed in Scilit:
- Substance use disorders in prisoners: an updated systematic review and meta‐regression analysis in recently incarcerated men and womenAddiction, 2017
- Incident opioid drug use and adverse respiratory outcomes among older adults with COPDEuropean Respiratory Journal, 2016
- Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic reviewDrug and Alcohol Dependence, 2013
- Extent of illicit drug use and dependence, and their contribution to the global burden of diseaseThe Lancet, 2012
- Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosingDrug and Alcohol Dependence, 2011
- Drug markets during the Katrina disasterDisaster Prevention and Management: An International Journal, 2011
- Alcohol Abuse/Dependence Symptoms Among Hospital Employees Exposed to a SARS Outbreak: Table 1Alcohol and Alcoholism, 2008
- Homelessness amongst drug users: a double jeopardy exploredInternational Journal of Drug Policy, 2001
- Deaths Attributable to Methadone vs Buprenorphine in FranceJAMA, 2001
- Deaths Attributable to Methadone vs Buprenorphine in FranceJAMA, 2001